- Home
- Publications
- Publication Search
- Publication Details
Title
Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 7, Pages 949-959
Publisher
Informa Healthcare
Online
2012-05-22
DOI
10.1517/13543784.2012.689287
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial
- (2017) P. Tang et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results
- (2017) D. Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy
- (2017) C. R. Garrett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).
- (2017) M. S. Kies et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
- (2017) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
- (2011) N. Starling et al. ANNALS OF ONCOLOGY
- The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
- (2011) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
- (2011) C. Lieu et al. CLINICAL CANCER RESEARCH
- An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
- (2011) Edward Chu Clinical Colorectal Cancer
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma
- (2011) Tina Cascone et al. JOURNAL OF CLINICAL INVESTIGATION
- Ramucirumab (IMC-1121B): a novel attack on angiogenesis
- (2010) Jennifer L Spratlin et al. Future Oncology
- Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer
- (2009) E. Chen et al. CLINICAL CANCER RESEARCH
- Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors
- (2009) W. Castillo-Avila et al. CLINICAL CANCER RESEARCH
- Phase III Trial of FOLFOX plus Bevacizumab or Cediranib (AZD2171) as First-Line Treatment of Patients with Metastatic Colorectal Cancer: HORIZON III
- (2009) Jane D. Robertson et al. Clinical Colorectal Cancer
- Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
- (2009) Quincy Siu-Chung Chu EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
- (2009) A. Craig Lockhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts
- (2008) Albana Cumashi et al. CANCER LETTERS
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation
- (2008) A. Kadenhe-Chiweshe et al. MOLECULAR CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started